Inflammation and lithium: Clues to mechanisms contributing to suicide-linked traits

Translational Psychiatry

Volumn 4, Issue 12, 2014, Pages

  Beurel, E ^a   Jope, R S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; LITHIUM;

AGGRESSION; BIOLOGICAL TRAIT; CENTRAL NERVOUS SYSTEM; DEPRESSION; ENDOPHENOTYPE; HUMAN; HYPOTHESIS; IMPULSIVENESS; INFLAMMATION; MENTAL STRESS; NONHUMAN; REVIEW; SUICIDAL BEHAVIOR; SUICIDE; UNITED STATES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

AGGRESSION; ANIMALS; DEPRESSION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMPULSIVE BEHAVIOR; INFLAMMATION; LITHIUM; STRESS, PSYCHOLOGICAL; SUICIDE;

EID: 84927785897     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.129     Document Type: Review

References (212)

1. Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003; 4: 819-828.
2. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: 205-228.
3. Koller G, Preuss UW, Bottlender M, Wenzel K, Soyka M. Impulsivity and aggression as predictors of suicide attempts in alcoholics. Eur Arch Psychiatry Clin Neurosci 2002; 252: 155-160.
4. Joiner TE Jr, Brown JS, Wingate LR. The psychology and neurobiology of suicidal behavior. Annu Rev Psychol 2005; 56: 287-314.
5. Kovacsics CE, Gottesman II, Gould TD. Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 2009; 49: 175-198.
6. Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc 2009; 18: 179-183.
7. Malkesman O, Pine DS, Tragon T, Austin DR, Henter ID, Chen G et al. Animal models of suicide-trait-related behaviors. Trends Pharmacol Sci 2009; 30: 165-173.
8. Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010; 62: 43-49.
9. Dalca IM, McGirr A, Renaud J, Turecki G. Gender-specific suicide risk factors: a case-control study of individuals with major depressive disorder. J Clin Psychiatry 2013; 74: 1209-1216.
10. De Jager PL, Bennett DA. An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome. JAMA Neurol 2013; 70: 719-726.
11. Kannan G, Sawa A, Pletnikov MV. Mouse models of gene-environment interactions in schizophrenia. Neurobiol Dis 2013; 57: 5-11.
12. Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009; 11(Suppl 2): 34-44.
13. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819.
14. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-639.
15. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380-383.
16. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
17. Vita A, De Peri L, Sacchetti E. Lithium in drinking water and suicide prevention: a review of the evidence. Int Clin Psychopharmacol 2014 (in press).
18. Mann JJ. The serotonergic system in mood disorders and suicidal behaviour. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120537.
19. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR et al. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci 1998; 18: 2239-2246.
20. Nguyen KT, Deak T, Will MJ, Hansen MK, Hunsaker BN, Fleshner M et al. Timecourse and corticosterone sensitivity of the brain, pituitary, and serum interleukin-1beta protein response to acute stress. Brain Res 2000; 859: 193-201.
21. Quan N, Avitsur R, Stark JL, He L, Shah M, Caligiuri M et al. Social stress increases the susceptibility to endotoxic shock. J Neuroimmunol 2001; 115: 36-45.
22. Johnson JD, O'Connor KA, Deak T, Stark M, Watkins LR, Maier SF et al. Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav Immun 2002; 16: 461-476.
23. Madrigal JL, Hurtado O, Moro MA, Lizasoain I, Lorenzo P, Castrillo A et al. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. Neuropsychopharmacology 2002; 26: 155-163.
24. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003; 100: 1920-1925.
25. Johnson JD, O'Connor KA, Hansen MK, Watkins LR, Maier SF. Effects of prior stress on LPS-induced cytokine and sickness responses. Am J Physiol Regul Integr Comp Physiol 2003; 284: 422-432.
26. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R et al. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003; 100: 9090-9095.
27. Johnson JD, O'Connor KA, Stark M, Watkins LR, Maier SF. The role of IL-1beta in stress-induced sensitization of proinflammatory cytokine and corticosterone responses. Neuroscience 2004; 127: 569-577.
28. Munhoz C, Madrigal JL, Garciá-Bueno B, Pradillo JM, Moro MA, Lizasoain I et al. TNF-alpha accounts for short-term persistence of oxidative status in rat brain after two weeks of repeated stress. Eur J Neurosci 2004; 20: 1125-1130.
29. Avitsur R, Kavelaars A, Heijnen C, Sheridan JF. Social stress and the regulation of tumor necrosis factor-alpha secretion. Brain Behav Immun 2005; 19: 311-317.
30. Viswanathan K, Daugherty C, Dhabhar FS. Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity. Int Immunol 2005; 17: 1059-1069.
31. Munhoz CD, Lepsch LB, Kawamoto EM, Malta MB, de Sá Lima L, Avellar MCW et al. Chronic unpredictable stress exacerbates lipopolysaccharide-induced activation of nuclear factor-B in the frontal cortex and hippocampus via glucocorticoid secretion. J Neuroscience 2006; 26: 3813-3820.
32. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006; 163: 1630-1633.
33. Steptoe A, Hamer M, Chida Y. The effect of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 2007; 7: 901-912.
34. Miller GE, Chen E, Sze J, Marin T, Arevalo JM, Doll R et al. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol Psychiatry 2008; 64: 266-272.
35. Bailey MT, Kinsey SG, Padgett DA, Sheridan JF, Leblebicioglu B. Social stress enhances IL-1and TNF-production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells. Physiol Behav 2009; 98: 351-358.
36. Blandino P Jr, Barnum CJ, Solomon LG, Larish Y, Lankow BS, Deak T et al. Gene expression changes in the hypothalamus provide evidence for regionallyselective changes in IL-1 and microglial markers after acute stress. Brain Behav Immun 2009; 23: 958-968.
37. Mays JW, Bailey MT, Hunzeker JT, Powell ND, Papenfuss T, Karlsson EA et al. Influenza virus-specific immunological memory is enhanced by repeated social defeat. J Immunol 2010; 184: 2014-2025.
38. Miller GE, Chen E. Harsh family climate in early life presages the emergence of a proinflammatory phenotype in adolescence. Psychol Sci 2010; 21: 848-856.
39. Audet MC, Jacobson-Pick S, Wann BP, Anisman H. Social defeat promotes specific cytokine variations within the prefrontal cortex upon subsequent aggressive or endotoxin challenges. Brain Behav Immun 2011; 25: 1197-1205.
40. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol 2011; 11: 625-632.
41. Powell ND, Mays JW, Bailey MT, Hanke ML, Sheridan JF. Immunogenic dendritic cells primed by social defeat enhance adaptive immunity to influenza A virus. Brain Behav Immun 2011; 25: 46-52.
42. Gárate I, Garciá-Bueno B, Madrigal JL, Bravo L, Berrocoso E, Caso JR et al. Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation 2011; 8: 151.
43. Gárate I, Garcia-Bueno B, Madrigal JL, Caso JR, Alou L, Gomez-Lus ML et al. Stressinduced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry 2013; 73: 32-43.
44. McQuaid RJ, Audet MC, Jacobson-Pick S, Anisman H. Environmental enrichment influences brain cytokine variations elicited by social defeat in mice. Psychoneuroendocrinology 2013; 38: 987-996.
45. Gárate I, Garciá-Bueno B, Madrigal JL, Caso JR, Alou L, Gómez-Lus ML et al. Tolllike 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation 2014; 11: 8.
46. Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 2013; 18: 15-37.
47. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311: 1-16.
48. Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci 2011; 34: 269-281.
49. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277: 15107-15112.
50. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-1179.
51. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S et al. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 2011; 31: 593-605.
52. Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010; 48: 1121-1132.
53. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013-1021.
54. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173: 3916-3924.
55. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104: 13798-13803.
56. Acosta C, Davies A. Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons. J Neurosci Res 2008; 86: 1077-1086.
57. Sloane JA, Blitz D, Margolin Z, Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromolecular Med 2010; 12: 149-163.
58. van Noort JM, Bsibsi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog Brain Res 2009; 175: 139-148.
59. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007; 190: 28-33.
60. Nässberger L, Träskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr Scand 1993; 88: 48-52.
61. Kim YK, Lee SW, Kim SH, Shim SH, Han SW, Choi SH et al. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 356-361.
62. Malkesman O, Pine DS, Tragon T, Austin DR, Henter ID, Chen G et al. Animal models of suicide-trait-related behaviors. Trends Pharmacol Sci 2009; 30: 165-173.
63. Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010; 62: 43-49.
64. Dalca IM, McGirr A, Renaud J, Turecki G. Gender-specific suicide risk factors: a case-control study of individuals with major depressive disorder. J Clin Psychiatry 2013; 74: 1209-1216.
65. De Jager PL, Bennett DA. An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome. JAMA Neurol 2013; 70: 719-726.
66. Kannan G, Sawa A, Pletnikov MV. Mouse models of gene-environment interactions in schizophrenia. Neurobiol Dis 2013; 57: 5-11.
67. Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009; 11(Suppl 2): 34-44.
68. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819.
69. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-639.
70. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380-383.
71. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
72. Vita A, De Peri L, Sacchetti E. Lithium in drinking water and suicide prevention: a review of the evidence. Int Clin Psychopharmacol 2014 (in press).
73. Mann JJ. The serotonergic system in mood disorders and suicidal behaviour. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120537.
74. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR et al. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci 1998; 18: 2239-2246.
75. Nguyen KT, Deak T, Will MJ, Hansen MK, Hunsaker BN, Fleshner M et al. Timecourse and corticosterone sensitivity of the brain, pituitary, and serum interleukin-1beta protein response to acute stress. Brain Res 2000; 859: 193-201.
76. Quan N, Avitsur R, Stark JL, He L, Shah M, Caligiuri M et al. Social stress increases the susceptibility to endotoxic shock. J Neuroimmunol 2001; 115: 36-45.
77. Johnson JD, O'Connor KA, Deak T, Stark M, Watkins LR, Maier SF et al. Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav Immun 2002; 16: 461-476.
78. Madrigal JL, Hurtado O, Moro MA, Lizasoain I, Lorenzo P, Castrillo A et al. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. Neuropsychopharmacology 2002; 26: 155-163.
79. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003; 100: 1920-1925.
80. Johnson JD, O'Connor KA, Hansen MK, Watkins LR, Maier SF. Effects of prior stress on LPS-induced cytokine and sickness responses. Am J Physiol Regul Integr Comp Physiol 2003; 284: 422-432.
81. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R et al. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003; 100: 9090-9095.
82. Johnson JD, O'Connor KA, Stark M, Watkins LR, Maier SF. The role of IL-1beta in stress-induced sensitization of proinflammatory cytokine and corticosterone responses. Neuroscience 2004; 127: 569-577.
83. Munhoz C, Madrigal JL, Garciá-Bueno B, Pradillo JM, Moro MA, Lizasoain I et al. TNF-alpha accounts for short-term persistence of oxidative status in rat brain after two weeks of repeated stress. Eur J Neurosci 2004; 20: 1125-1130.
84. Avitsur R, Kavelaars A, Heijnen C, Sheridan JF. Social stress and the regulation of tumor necrosis factor-alpha secretion. Brain Behav Immun 2005; 19: 311-317.
85. Viswanathan K, Daugherty C, Dhabhar FS. Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity. Int Immunol 2005; 17: 1059-1069.
86. Munhoz CD, Lepsch LB, Kawamoto EM, Malta MB, de Sá Lima L, Avellar MCW et al. Chronic unpredictable stress exacerbates lipopolysaccharide-induced activation of nuclear factor-B in the frontal cortex and hippocampus via glucocorticoid secretion. J Neuroscience 2006; 26: 3813-3820.
87. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006; 163: 1630-1633.
88. Steptoe A, Hamer M, Chida Y. The effect of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 2007; 7: 901-912.
89. Miller GE, Chen E, Sze J, Marin T, Arevalo JM, Doll R et al. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol Psychiatry 2008; 64: 266-272.
90. Bailey MT, Kinsey SG, Padgett DA, Sheridan JF, Leblebicioglu B. Social stress enhances IL-1and TNF-production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells. Physiol Behav 2009; 98: 351-358.
91. Blandino P Jr, Barnum CJ, Solomon LG, Larish Y, Lankow BS, Deak T et al. Gene expression changes in the hypothalamus provide evidence for regionallyselective changes in IL-1 and microglial markers after acute stress. Brain Behav Immun 2009; 23: 958-968.
92. Mays JW, Bailey MT, Hunzeker JT, Powell ND, Papenfuss T, Karlsson EA et al. Influenza virus-specific immunological memory is enhanced by repeated social defeat. J Immunol 2010; 184: 2014-2025.
93. Miller GE, Chen E. Harsh family climate in early life presages the emergence of a proinflammatory phenotype in adolescence. Psychol Sci 2010; 21: 848-856.
94. Audet MC, Jacobson-Pick S, Wann BP, Anisman H. Social defeat promotes specific cytokine variations within the prefrontal cortex upon subsequent aggressive or endotoxin challenges. Brain Behav Immun 2011; 25: 1197-1205.
95. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol 2011; 11: 625-632.
96. Powell ND, Mays JW, Bailey MT, Hanke ML, Sheridan JF. Immunogenic dendritic cells primed by social defeat enhance adaptive immunity to influenza A virus. Brain Behav Immun 2011; 25: 46-52.
97. Gárate I, Garciá-Bueno B, Madrigal JL, Bravo L, Berrocoso E, Caso JR et al. Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation 2011; 8: 151.
98. Gárate I, Garcia-Bueno B, Madrigal JL, Caso JR, Alou L, Gomez-Lus ML et al. Stressinduced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry 2013; 73: 32-43.
99. McQuaid RJ, Audet MC, Jacobson-Pick S, Anisman H. Environmental enrichment influences brain cytokine variations elicited by social defeat in mice. Psychoneuroendocrinology 2013; 38: 987-996.
100. Gárate I, Garciá-Bueno B, Madrigal JL, Caso JR, Alou L, Gómez-Lus ML et al. Tolllike 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation 2014; 11: 8.
101. Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 2013; 18: 15-37.
102. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311: 1-16.
103. Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci 2011; 34: 269-281.
104. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277: 15107-15112.
105. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-1179.
106. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S et al. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 2011; 31: 593-605.
107. Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010; 48: 1121-1132.
108. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013-1021.
109. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173: 3916-3924.
110. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104: 13798-13803.
111. Acosta C, Davies A. Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons. J Neurosci Res 2008; 86: 1077-1086.
112. Sloane JA, Blitz D, Margolin Z, Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromolecular Med 2010; 12: 149-163.
113. van Noort JM, Bsibsi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog Brain Res 2009; 175: 139-148.
114. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007; 190: 28-33.
115. Nässberger L, Träskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr Scand 1993; 88: 48-52.
116. Kim YK, Lee SW, Kim SH, Shim SH, Han SW, Choi SH et al. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 356-361.
117. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009; 66: 287-292.
118. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011; 25: 335-339.
119. Lindqvist D, Janelidze S, Erhardt S, Träskman-Bendz L, Engström G, Brundin L et al. CSF biomarkers in suicide attempters-a principal component analysis. Acta Psychiatr Scand 2011; 124: 52-61.
120. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151-157.
121. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008; 117: 198-206.
122. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 2012; 46: 57-63.
123. Baron DA, Hardie T, Baron SH. Possible association of interleukin-2 treatment with depression and suicide. J Am Osteopath Assoc 1993; 93: 799-800.
124. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21: 241-243.
125. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML et al. Suicidal ideation during interferon-2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26: 237-240.
126. Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC, Gomes S et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol 2010; 33: 312-318.
127. Pandey GN, Rizavi HS, Ren X, Bhaumik R, Dwivedi Y. Toll-like receptors in the depressed and suicide brain. J Psychiatr Res 2014; 53: 62-68.
128. Mendlovic S, Mozes E, Eilat E, Doron A, Lereya J, Zakuth V et al. Immune activation in non-treated suicidal major depression. Immunol Lett 1999; 67: 105-108.
129. Sequeira A, Klempan T, Canetti L, ffrench-Mullen J, Benkelfat C, Rouleau GA et al. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 2007; 12: 640-655.
130. Thalmeier A, Dickmann M, Giegling I, Schneider B, M Hartmann A, Maurer K et al. Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. Int J Neuropsychopharmacol 2008; 11: 217-228.
131. Galfalvy H, Zalsman G, Huang YY, Murphy L, Rosoklija G, Dwork AJ et al. A pilot genome wide association and gene expression array study of suicide with and without major depression. World J Biol Psychiatry 2013; 14: 574-582.
132. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011; 25: 1272-1278.
133. Mann JJ, Currier DM. Stress, genetics and epigenetic effects on the neurobiology of suicidal behavior and depression. Eur Psychiatry 2010; 25: 268-271.
134. Mann JJ, Arango VA, Avenevoli S, Brent DA, Champagne FA, Clayton P et al. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 2009; 65: 556-563.
135. Zalcman SS, Siegel A. Neurobiology of aggression and rage: role of cytokines. Brain Behav Immunity 2006; 20: 507-514.
136. Suarez EC, Lewis JG, Kuhn C. The relation of aggression, hostility, and anger to lipopolysaccharide-stimulated tumor necrosis factor (TNF)-alpha by blood monocytes from normal men. Brain Behav Immun 2002; 16: 675-684.
137. Coccaro EF. Association of C-reactive protein elevation with trait aggression and hostility in personality disordered subjects: a pilot study. J Psychiatr Res 2006; 40: 460-465.
138. Marsland AL, Prather AA, Petersen KL, Cohen S, Manuck SB. Antagonistic characteristics are positively associated with inflammatory markers independently of trait negative emotionality. Brain Behav Immun 2008; 22: 753-761.
139. Coccaro EF, Lee R, Coussons-Read M. Elevated plasma inflammatory markers in individuals with intermittent explosive disorder and correlation with aggression in humans. JAMA Psychiatry 2014; 71: 158-165.
140. Mommersteeg PM, Vermetten E, Kavelaars A, Geuze E, Heijnen CJ. Hostility is related to clusters of T-cell cytokines and chemokines in healthy men. Psychoneuroendocrinology 2008; 33: 1041-1050.
141. Ahrén-Moonga J, Lekander M, von Blixen N, Rönnelid J, Holmgren S, af Klinteberg B et al. Levels of tumour necrosis factor-alpha and interleukin-6 in severely ill patients with eating disorders. Neuropsychobiology 2011; 63: 8-14.
142. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML. Interferon-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New Eng J Med 1998; 339: 1485-1492.
143. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708-714.
144. Petitto JM, Lysle DT, Gariepy JL, Lewis MH. Association of genetic differences in social behavior and cellular immune responsiveness: effects of social experience. Brain Behav Immun 1994; 8: 111-122.
145. Patel A, Siegel A, Zalcman SS. Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav Immun 2010; 24: 1276-1280.
146. Bierbrauer J Nilsson A Müller-Oerlinghausen B Bauer M. Therapeutic and prophylactic effects of lithium on pathological aggression. In: Bauer, M, Grof, P, Müller-Oerlinghausen, B (eds). Lithium in Neuropsychiatry. Informa Healthcare, Abingdon, UK, 2006, 227-236.
147. Kovacsics CE, Gould TD. Shock-induced aggression in mice is modified by lithium. Pharmacol Biochem Behav 2010; 94: 380-386.
148. O'Donnell KC, Gould TD. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev 2007; 31: 932-962.
149. Sutin AR, Terracciano A, Deiana B, Naitza S, Ferrucci L, Uda M et al. High neuroticism and low conscientiousness are associated with interleukin-6. Psychol Med 2010; 40: 1485-1493.
150. Sutin AR, Milaneschi Y, Cannas A, Ferrucci L, Uda M, Schlessinger D et al. Impulsivity-related traits are associated with higher white blood cell counts. J Behav Med 2012; 35: 616-623.
151. Dorrego MF, Canevaro L, Kuzis G, Sabe L, Starkstein SE. A randomized, doubleblind, crossover study of methylphenidate and lithium in adults with attentiondeficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 2002; 14: 289-295.
152. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002; 26: 530-536.
153. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disordersAm J Psychiatry 2005; 162: 137-145.
154. Higgins GA, Breysse N. Rodent model of attention: the 5-choice serial reaction time task. Curr Protoc Pharmacol 2008; Chapter 5, Unit 5.49.
155. Galtress T, Garcia A, Kirkpatrick K. Individual differences in impulsive choice and timing in rats. J Exp Anal Behav 2012; 98: 65-87.
156. Ohmura Y, Tsutsui-Kimura I, Kumamoto H, Minami M, Izumi T, Yamaguchi T et al. Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats. Psychopharmacology 2012; 219: 421-432.
157. Halcomb ME, Gould TD, Grahame NJ. Lithium, but not valproate, reduces impulsive choice in the delay discounting task in mice. Neuropsychopharmacology 2013; 38: 1937-1944.
158. Hayley S, Poulter M.O, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor-and cytokine-induced alterations of neuroplasticity. Neuroscience 2005; 135: 659-678.
159. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
160. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007; 21: 153-160.
161. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
162. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
163. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009; 9: 429-439.
164. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16: 751-762.
165. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009; 65: 344-348.
166. Kullmann JS, Grigoleit JS, Lichte P, Kobbe P, Rosenberger C, Banner C et al. Neural response to emotional stimuli during experimental human endotoxemia. Hum Brain Mapp 2013; 34: 2217-2227.
167. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokineassociated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-452.
168. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 2003; 35: 2-11.
169. Gabbay V, Klein RG, Alonso CM, Babb JS, Nishawala M, De Jesus G et al. Immune system dysregulation in adolescent major depressive disorder. J Affect Disord 2009; 115: 177-182.
170. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007; 41: 326-331.
171. Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C et al. Antiinflammatory properties of desipramine and fluoxetine. Respir Res 2007; 3: 8-35.
172. Chourbaji S, Urani A, Inta I, Sanchis-Segura C, Brandwein C, Zink M et al. IL-6 knockout mice exhibit resistance to stress-induced development of depressionlike behaviors. Neurobiol Dis 2006; 23: 587-954.
173. Simen BB, Duman CH, Simen AA, Duman RS. TNFsignaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006; 59: 775-785.
174. Koo JW, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs 2009; 10: 664-671.
175. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011; 16: 1068-1070.
176. O'Brien WT, Harper AD, Jové F, Woodgett JR, Maretto S, Piccolo S et al. Glycogen synthase kinase-3haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24: 6791-6798.
177. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005; 24: 1571-1583.
178. Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010; 35: 1761-1774.
179. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007; 61: 240-245.
180. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008; 105: 1333-1338.
181. Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberté C et al. Abnormalities in brain structure and behavior in GSK-3mutant mice. Mol Brain 2009; 2: 35.
182. Jiménez E, Arias B, Mitjans M, Goikolea JM, Roda E, Ruíz V et al. Association between GSK3gene and increased impulsivity in bipolar disorder. Eur Neuropsychopharmacol 2014; 24: 510-518.
183. Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 2011; 4: 16-26.
184. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387-390.
185. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on-catenin in mouse hippocampus. Biol Psychiatry 2004; 55: 781-784.
186. Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H et al. Role of glycogen synthase kinase-3in early depressive behavior induced by mild traumatic brain injury. Mol Cell Neurosci 2007; 34: 571-577.
187. Silva R, Mesquita AR, Bessa J, Sousa JC, Sotiropoulos I, Leaõ P et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3. Neuroscience 2008; 152: 656-669.
188. Wilkinson MB, Dias C, Magida J, Mazei-Robison M, Lobo M, Kennedy P et al. A novel role of the WNT-dishevelled-GSK3signaling cascade in the mouse nucleus accumbens in a social defeat model of depression. J Neurosci 2011; 31: 9084-9092.
189. Okamoto H, Voleti B, Banasr M, Sarhan M, Duric V, Girgenti M. J et al. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry 2010; 68: 521-527.
190. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS et al. In vivo regulation of glycogen synthase kinase-3(GSK3) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29: 1426-1431.
191. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
192. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
193. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158-1164.
194. Jope RS. Lithium and GSK3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-443.
195. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 2009; 21: 264-273.
196. Beurel E, Jope RS. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem 2008; 283: 21934-21944.
197. Beurel E, Jope RS. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation 2009; 6: 9-20.
198. Beurel E, Jope RS. Glycogen synthase kinase-3 promotes the synergistic action of interferon-on lipopolysaccharide-induced IL-6 production in RAW264.7 cells. Cell Signalling 2009; 21: 978-985.
199. Beurel E, Jope RS. Glycogen synthase kinase-3 controls inflammatory tolerance in astrocytes. Neuroscience 2010; 169: 1063-1070.
200. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010; 31: 24-31.
201. Beurel E, Wen-I Y, Michalek SM, Harrington LE, Jope RS. Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells. J Immunol 2011; 186: 1391-1398.
202. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6: 777-784.
203. Tsai C.C, Kai J.I, Huang W.C, Wang C.Y, Wang Y, Chen C.L et al. Glycogen synthase kinase-3facilitates IFN-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J Immunol 2009; 183: 856-864.
204. Turnquist HR, Cardinal J, Macedo C, Rosborough BR, Sumpter TL, Geller DA et al. mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 2010; 115: 4758-4769.
205. Beurel E. Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci 2011; 4: 18.
206. Beurel E, Jope RS. The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006; 79: 173-189.
207. Hu X, Paik PK, Chen J, Yarilina A, Kockeritz L, Lu TT et al. IFN-suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 2006; 24: 563-574.
208. Cuzzocrea S, Mazzon E, Di Paola R, Muia C, Crisafulli C, Dugo L et al. Glycogen synthase kinase-3inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 2006; 120: 57-67.
209. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM et al. GSK-3inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005; 33: 1903-1912.
210. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C et al. Reduction of exp erimental colitis in the rat by inhibitors of glycogen synthase kinase-3. Br J Pharmacol 2006; 147: 575-582.
211. Yu F, Wang Z, Tchantchou F, Chiu CT, Zhang Y, Chuang DM et al. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J Neurotrauma 2012; 29: 362-374.
212. Beurel E, Kaidanovich-Beilin O, Yeh WI, Song L, Palomo V, Michalek SM et al. Regulation of Th1 cells and experimental autoimmune encephalomyelitis (EAE) by glycogen synthase kinase-3. J Immunol 2013; 190: 5000-5011.